BMS looks to new products not acquisitions to drive Japanese growth
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb sees strong growth potential in Japan, a market where its sales have suffered in recent years, and is hoping that the launch of several key new products there over the next four years will take it into the local pharma top 20.